2. Characteristics of Smoflipid®
  3. Composition

Smoflipid® Composition

Smoflipid® is a new advancement in U.S. lipid emulsions for adults

plus

α-tocopherol (approx. 200 mg/L) is an important antioxidant that protects long-chain polyunsaturated fats from peroxidation.3,4

 

See full Prescribing Information for composition of Smoflipid.

References

  1. Deckelbaum RJ, et al. Medium-chain versus long-chain triacylglycerol emulsion hydrolysis by lipoprotein lipase and hepatic lipase: implications for the mechanisms of lipase action. Biochemistry (Mosc). 1990;29(5):1136-1142.
  2. Kalish BT, Fallon EM, Puder M. JPEN J Parenter Enteral Nutr. 2012;36:380-8.
  3. Burrin DG, et al. Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr. 2014;5(1):82-91.
  4. Biesalski HK. Vitamin E requirements in parenteral nutrition. Gastroenterology. 2009;137(5 Suppl):S92-S104.
  5. Bach AC, et al. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982;36(5):950-962.
  6. Vanek VW, et al. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192.

Important Safety Information

Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs. NAROPIN may be associated with adverse reactions which are characteristic of those associated with other amide-type local anesthetics.1 In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.

Please see Full Prescribing Information.

1. NAROPIN Prescribing Information Data on file.

NAROPIN is indicated for the production of local or regional anesthesia for surgery and acute pain management.

NAROPIN and logo are registered trademarks of Fresenius Kabi USA, LLC. ©2015, Fresenius Kabi USA, LLC. All Rights Reserved.